OpenURL Connection Search

Select item for more details and to access through your institution.

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 1, p. 74, doi. 10.1002/psp4.12877
By:
- Krause, Andreas;
- Lott, Dominik;
- Brussee, Janneke M.;
- Muehlan, Clemens;
- Dingemanse, Jasper
Publication type:
Article
Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life.
Published in:
Journal of Clinical Pharmacology, 2021, v. 61, n. 1, p. 82, doi. 10.1002/jcph.1701
By:
- Krause, Andreas;
- Lott, Dominik;
- Dingemanse, Jasper
Publication type:
Article
Modeling the Effect of the Selective S1P Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes.
Published in:
Pharmaceutical Research, 2017, v. 34, n. 3, p. 599, doi. 10.1007/s11095-016-2087-x
By:
- Lott, Dominik;
- Krause, Andreas;
- Seemayer, Christian;
- Strasser, Daniel;
- Dingemanse, Jasper;
- Lehr, Thorsten
Publication type:
Article
Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.083055
By:
- Schwab, Dietmar;
- Jolivet, Sebastien;
- Gibiansky, Leonid;
- Lott, Dominik
Publication type:
Article
GRADUATE I and II: Subgroup analysis and correlations of biomarkers.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082995
By:
- Bittner, Tobias;
- Belousov, Anton;
- Lane, Christopher;
- Schwab, Dietmar;
- Klein, Gregory;
- Tonietto, Matteo;
- Lott, Dominik;
- Illiano, Vittorio P;
- Blennow, Kaj;
- Barkhof, Frederik;
- Smith, Janice;
- Doody, Rachelle S.
Publication type:
Article
Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist.
Published in:
Basic & Clinical Pharmacology & Toxicology, 2019, v. 124, n. 6, p. 711, doi. 10.1111/bcpt.13197
By:
- Géhin, Martine;
- Lott, Dominik;
- Farine, Hervé;
- Issac, Milena;
- Strasser, Daniel;
- Sidharta, Patricia;
- Dingemanse, Jasper
Publication type:
Article
Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients.
Published in:
British Journal of Clinical Pharmacology, 2020, v. 86, n. 4, p. 791, doi. 10.1111/bcp.14182
By:
- Lott, Dominik;
- Juif, Pierre‐Eric;
- Dingemanse, Jasper;
- Krause, Andreas
Publication type:
Article
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
Published in:
British Journal of Clinical Pharmacology, 2017, v. 83, n. 3, p. 476, doi. 10.1111/bcp.13149
By:
- Stalder, Anna K.;
- Lott, Dominik;
- Strasser, Daniel S.;
- Cruz, Hans G.;
- Krause, Andreas;
- Groenen, Peter M.A.;
- Dingemanse, Jasper
Publication type:
Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
By:
- Mazer, Norman A;
- Lott, Dominik;
- Grimm, Hans Peter;
- Machacek, Matthias;
- Boess, Frank;
- Gieschke, Ronald;
- Klein, Gregory;
- Baudler, Monika;
- Doody, Rachelle S.
Publication type:
Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
By:
- Mazer, Norman A;
- Lott, Dominik;
- Grimm, Hans Peter;
- Machacek, Matthias;
- Boess, Frank;
- Gieschke, Ronald;
- Klein, Gregory;
- Baudler, Monika;
- Doody, Rachelle S.
Publication type:
Article
Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer's disease.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.063261
By:
- Neve, Anuja;
- Bullain, Szofia;
- Das, Bibha;
- Huang, Zhiyue;
- Watkin, Michelle;
- Delmar, Paul;
- Klein, Gregory;
- Bittner, Tobias;
- Lott, Dominik;
- Smith, Janice;
- Kerchner, Geoffrey A.;
- Fontoura, Paulo;
- Baudler, Monika;
- Doody, Rachelle S.
Publication type:
Article
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 6, p. 2287, doi. 10.1002/alz.12877
By:
- Mazer, Norman A.;
- Hofmann, Carsten;
- Lott, Dominik;
- Gieschke, Ronald;
- Klein, Gregory;
- Boess, Frank;
- Grimm, Hans Peter;
- Kerchner, Geoffrey A.;
- Baudler‐Klein, Monika;
- Smith, Janice;
- Doody, Rachelle S.
Publication type:
Article
Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 3, p. 1, doi. 10.1002/alz.067069
By:
- Mazer, Norman A;
- Hofmann, Carsten;
- Lott, Dominik;
- Gieschke, Ronald;
- Klein, Gregory;
- Boess, Frank;
- Grimm, Hans Peter;
- Kerchner, Geoffrey A.;
- Baudler, Monika;
- Smith, Janice;
- Schobel, Scott;
- Doody, Rachelle S.
Publication type:
Article
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Published in:
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12306
By:
- Aldea, Roxana;
- Grimm, Hans Peter;
- Gieschke, Ronald;
- Hofmann, Carsten;
- Lott, Dominik;
- Bullain, Szofia;
- Delmar, Paul;
- Klein, Gregory;
- Lyons, Marco;
- Piazza, Fabrizio;
- Carare, Roxana O.;
- Mazer, Norman A.
Publication type:
Article
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies.
Published in:
2017
By:
- Lott, Dominik;
- Lehr, Thorsten;
- Dingemanse, Jasper;
- Krause, Andreas
Publication type:
journal article
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod.
Published in:
Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 6, p. 1083, doi. 10.1002/cpt.877
By:
- Lehr, Thorsten;
- Lott, Dominik;
- Dingemanse, Jasper;
- Krause, Andreas
Publication type:
Article

Found: 16

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist.

Estimation of Attainment of Steady‐State Conditions for Compounds With a Long Half‐Life.

Modeling the Effect of the Selective S1P Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes.

Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies.

GRADUATE I and II: Subgroup analysis and correlations of biomarkers.

Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist.

Modelling pharmacokinetics and pharmacodynamics of the selective S1P<sub>1</sub> receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients.

Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.

Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.

Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer's disease.

Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).

Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment.

In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.

Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod Based on 13 Clinical Studies.

Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod.